Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | EHA 2020 CLL highlights: CLL14 & CAPTIVATE

Paolo Ghia • 22 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Antibodies Chlorambucil Ibrutinib Obinutuzumab Venetoclax
CAPTIVATE CLL14

Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, explores highlights from EHA 2020, including the CLL14 trial (NCT02242942) investigating venetoclax-obinutuzumab in previously untreated, comorbid, chronic lymphocytic leukemia (CLL). The CAPTIVATE study (NCT02910583), which investigated measurable residual disease (MRD)-guided discontinuation and fixed duration therapy with the combination of ibrutinib and venetoclax is also discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Paolo Ghia

1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
2:20
Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Paolo Ghia • 8 Dec 2023
3:00
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Paolo Ghia • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals